Drug family · 3 brands

Semaglutide family — Wegovy, Ozempic, Rybelsus

GLP-1 receptor agonist. FDA-approved since 2017. Trial weight loss range: 8.4% (oral Rybelsus) up to 15% (injectable Wegovy).

Quick answer

semaglutide is a GLP-1 receptor agonist. FDA-approved brand-name medications containing semaglutide: Wegovy, Ozempic, Rybelsus. Trial weight loss varies from 8.4% (oral Rybelsus) up to 15% (injectable Wegovy). Each brand is FDA-approved for a specific indication; prescribers choose based on patient diagnosis and insurance coverage.

Manufacturer: Novo Nordisk
FDA indications: 3 — obesity, type 2 diabetes, cardiovascular risk reduction
Trial weight loss: 8.4-15%: Range across oral (Rybelsus) and injectable (Wegovy) forms
Frequency: Weekly (Wegovy/Ozempic) or daily (Rybelsus)
Compounded availability: Limited after FDA shortage end (2024): 503A pharmacies may compound for individualized clinical needs only

Mechanism of action

Semaglutide is a synthetic analog of the human glucagon-like peptide-1 (GLP-1) hormone, modified for resistance to DPP-4 enzymatic degradation. It binds the GLP-1 receptor stimulating glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and acting on central appetite regulation. The result: improved glycemic control in type 2 diabetes plus significant body weight loss in obesity.

FDA-approved brands containing semaglutide

All brands share active ingredient semaglutide but differ in indication, dosing, and formulation.

Wegovy

~15% loss

Chronic weight management

Subcutaneous injection (weekly)

FDA-approved 2021

See full Wegovy comparison

Ozempic

~14.9% loss

Type 2 diabetes

Subcutaneous injection (weekly)

FDA-approved 2017

See full Ozempic comparison

Rybelsus

See full Rybelsus comparison

Alternatives outside the semaglutide family

If semaglutide options don't fit, these GLP-1 medications use a different active ingredient:

Common questions

What is the difference between Wegovy and Ozempic?

Both contain semaglutide, but Wegovy is FDA-approved for chronic weight management (max dose 2.4mg weekly) and Ozempic for type 2 diabetes (max dose 2.0mg weekly). Same molecule, different dose ceilings and indications. Prescribers choose based on the FDA-approved indication that matches patient needs.

Is Rybelsus as effective as injectable semaglutide?

Rybelsus produces less weight loss (~8.4% trial average) compared to injectable semaglutide (~14.9-15%). Oral formulation has lower bioavailability and requires precise dosing on empty stomach. Patients with strong needle aversion may benefit despite reduced efficacy. Defer choice to prescriber.

Can I switch between Wegovy, Ozempic, and Rybelsus?

Switching between semaglutide formulations is possible but requires prescriber-supervised titration. Switching oral → injectable typically requires re-titration of injectable starting dose; switching injectable → oral typically requires higher equivalent oral dose. Insurance coverage often determines which formulation is accessible.

What's the long-term safety profile?

Semaglutide has been in FDA use with 2017 (Ozempic) and 2021 (Wegovy for weight loss). SELECT trial showed cardiovascular benefit in obesity without diabetes; SUSTAIN-6 showed similar in T2D. Black-box warning for medullary thyroid carcinoma risk; pancreatitis monitoring required. Long-term (>10 year) data still accumulating.

References

Browse other drug families

Drug family · 3 brands

Semaglutide family — Wegovy, Ozempic, Rybelsus

GLP-1 receptor agonist. FDA-approved since 2017. Trial weight loss range: 8.4% (oral Rybelsus) up to 15% (injectable Wegovy).

Quick answer

Manufacturer: Novo Nordisk
FDA indications: 3 — obesity, type 2 diabetes, cardiovascular risk reduction
Trial weight loss: 8.4-15%: Range across oral (Rybelsus) and injectable (Wegovy) forms
Frequency: Weekly (Wegovy/Ozempic) or daily (Rybelsus)
Compounded availability: Limited after FDA shortage end (2024): 503A pharmacies may compound for individualized clinical needs only